CJC-1295 + IPAMORELIN
- In stock, ready to ship
- Backordered, shipping soon
CJC-1295 + Ipamorelin
Research-Grade GH Secretagogue Combination
Product Overview
CJC-1295 + Ipamorelin is a synergistic research combination pairing CJC-1295 (a GHRH analogue) with Ipamorelin (a selective ghrelin receptor agonist). This dual-peptide formulation is designed to produce a potent stimulation of endogenous growth hormone (GH) secretion. Researchers utilize this blend to explore the intersection of hypothalamic and pituitary signaling in preclinical and in vitro models.
Key Research Applications
-
Dual-Pathway Stimulation: Targets both the GHRH and ghrelin receptor pathways simultaneously to amplify GH release.
-
Pulsatile GH Dynamics: Used to study natural GH pulse patterns, making it a primary model for endocrinology research.
-
Metabolic & IGF-1 Research: Investigated for its ability to increase hepatic IGF-1 production and influence body composition.
-
Regenerative Physiology: Evaluated in models focused on tissue recovery and accelerated repair mechanisms.
-
Receptor Selectivity: Features Ipamorelin, which is studied for its high selectivity and minimal impact on prolactin or cortisol levels.
Technical Specifications
-
Purity: >99% (confirmed via batch verification).
-
Formulation: 5/5mg (10mg total) lyophilized powder.
-
Molecular Formulas: C152H252N44O42 / C38H49N9O5.
Research Notice: CJC/Ipamorelin is strictly for laboratory research and analytical purposes. It is not intended for human or animal use, and is not approved for any therapeutic, diagnostic, or medical application.
